天宇股份原料药阿帕他胺通过CDE审评

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd., has recently passed the review by the National Medical Products Administration (NMPA) for the active pharmaceutical ingredient (API) Apalutamide, which is used in prostate cancer treatment [1] Group 1: Company Information - Tianyu Co., Ltd. has a subsidiary named Zhejiang Jingsheng Pharmaceutical Co., Ltd. that specializes in pharmaceutical production [1] - The company is focused on developing Apalutamide, a non-steroidal anti-androgen drug [1] Group 2: Product Details - Apalutamide is indicated for the treatment of prostate cancer, specifically non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer [1] - The drug works by inhibiting the androgen receptor signaling pathway, thereby delaying disease progression [1] - Apalutamide is intended to be used in conjunction with androgen deprivation therapy under medical supervision [1]